[go: up one dir, main page]

AR039846A1 - Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo - Google Patents

Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo

Info

Publication number
AR039846A1
AR039846A1 ARP030101782A ARP030101782A AR039846A1 AR 039846 A1 AR039846 A1 AR 039846A1 AR P030101782 A ARP030101782 A AR P030101782A AR P030101782 A ARP030101782 A AR P030101782A AR 039846 A1 AR039846 A1 AR 039846A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
molecula
muc
codifying
vivo
Prior art date
Application number
ARP030101782A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR039846A1 publication Critical patent/AR039846A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se refiere a unas construcciones nuevas de ácidos nucleicos, útiles en los protocolos de vacunación de ácidos nucleicos para el tratamiento y profilaxis de tumores que expresan MUC-1. En particular, el ácido nucleico es DNA y las construcciones de DNA comprenden un gen que codifica un derivado de MUC-1 que tiene menos de 10 unidades de repetición perfectas. La invención además proporciona composiciones farmacéuticas que comprenden dichas construcciones, particularmente composiciones farmacéuticas adaptadas para el suministro mediado por partícula, procedimientos para producirlos, y su uso en medicina. También se proporcionan proteínas nuevas codificadas por el ácido nucleico y composiciones farmacéuticas que las contienen.
ARP030101782A 2002-05-24 2003-05-22 Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo AR039846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines

Publications (1)

Publication Number Publication Date
AR039846A1 true AR039846A1 (es) 2005-03-02

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101782A AR039846A1 (es) 2002-05-24 2003-05-22 Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo

Country Status (20)

Country Link
US (1) US20060251665A1 (es)
EP (1) EP1527177A2 (es)
JP (1) JP2005526520A (es)
KR (1) KR20050004211A (es)
CN (1) CN100408682C (es)
AR (1) AR039846A1 (es)
AU (1) AU2003240729B2 (es)
BR (1) BR0311211A (es)
CA (1) CA2485816A1 (es)
GB (1) GB0212046D0 (es)
IL (1) IL165156A0 (es)
IS (1) IS7526A (es)
MX (1) MXPA04011527A (es)
NO (1) NO20044947L (es)
NZ (1) NZ536668A (es)
PL (1) PL374569A1 (es)
RU (1) RU2303069C2 (es)
TW (1) TW200407426A (es)
WO (1) WO2003100060A2 (es)
ZA (1) ZA200409445B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005046614A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation System for treating and preventing breast cancer
JP5285855B2 (ja) * 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
CA2595778A1 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. Anti-muc1 .alpha..beta. antibodies
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CN103209701B (zh) * 2010-06-11 2016-08-03 乔治亚大学研究基金公司 免疫原性疫苗
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
AU2012222188A1 (en) * 2011-02-24 2013-08-15 Oncothyreon Inc. MUC1 based glycolipopeptide vaccine with adjuvant
TWI654302B (zh) * 2016-01-19 2019-03-21 輝瑞股份有限公司 癌症疫苗
NZ752275A (en) * 2016-09-28 2025-07-25 Bavarian Nordic As Compositions and methods for enhancing the stability of transgenes in poxviruses
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0863984T3 (da) * 1995-11-30 2006-08-28 Univ Texas Fremgangsmåder og præparater til behandling af cancer
AU727308B2 (en) * 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
DE60030450T2 (de) * 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
US20020142047A1 (en) * 2001-01-19 2002-10-03 Johnson Mark E. Microsphere delivery of mucin peptides
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003089574A2 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
JP2005526520A (ja) 2005-09-08
CN1668746A (zh) 2005-09-14
RU2303069C2 (ru) 2007-07-20
EP1527177A2 (en) 2005-05-04
US20060251665A1 (en) 2006-11-09
MXPA04011527A (es) 2005-09-30
WO2003100060A3 (en) 2004-02-19
AU2003240729B2 (en) 2007-12-20
IL165156A0 (en) 2005-12-18
IS7526A (is) 2004-11-11
GB0212046D0 (en) 2002-07-03
BR0311211A (pt) 2005-03-01
CN100408682C (zh) 2008-08-06
KR20050004211A (ko) 2005-01-12
AU2003240729A1 (en) 2003-12-12
TW200407426A (en) 2004-05-16
NZ536668A (en) 2007-01-26
NO20044947D0 (no) 2004-11-12
NO20044947L (no) 2005-12-16
PL374569A1 (en) 2005-10-31
RU2004134331A (ru) 2005-08-27
WO2003100060A2 (en) 2003-12-04
ZA200409445B (en) 2006-02-22
CA2485816A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AR039846A1 (es) Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
ATE510011T1 (de) Neue pilzproteine und diese codierende nukleinsäuren
EP4494652A3 (en) Cancer rna-vaccine
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
WO2004067706A3 (en) Production of multimeric proteins
MX2016008551A (es) Moleculas artificiales de acido nucleico.
CL2009000648A1 (es) Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02).
AR020601A1 (es) Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
CL2019003409A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
RU2435851C2 (ru) Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические иммуномодулирующие профили
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
DE69927249D1 (de) Induzierendes alphavirengen- expressionssystem
AR041086A1 (es) Vacuna
ATE520708T1 (de) Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
DE60204317D1 (de) Methode zur plasmidstabilisierung durch in vivo deletion der antibiotikaresistenz und selektion mit einem essentiellen gen
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
ECSP23043458A (es) Inmunocitoquina para activar el receptor IL-10Ra humano y su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure